Synthesis, crystal structure analysis, spectral investigations (NMR, FT-IR, UV), DFT calculations, ADMET studies, molecular docking and anticancer activity of 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine - A novel potent human topoisomerase IIα inhibitor

Previous research studies confirm that molecules containing 1,2,3-triazole moiety are potential anticancer agents which elevates effectiveness and reduces drug resistance. Present study was aimed to evaluate the anticancer activity of the synthesized novel title compound 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine (BTCP). The structural and spectral characteristics of BTCP were studied and compared with DFT results. NBO, HOMO and LUMO energies, Mulliken atomic charges and molecular electrostatic potential surface were investigated. The bioavailability of BTCP was confirmed by pharmacological investigations using Molinspiration and PreADMET online servers. Molecular docking studies verified the inhibitory nature of BTCP against human topoisomerase ll alpha enzyme (1ZXM) over standard drug doxorubicin. MIT assay technique has been employed to study anticancer activity of BTCP with three human cancer cell lines (A549, MDAMB-231, PC-3) along with existing drug doxorubicin. The results of docking and anticancer activity specify that BTCP could be regarded as an alternative anticancer drug. (C) 2018 Elsevier B.V. All rights reserved.